Calibrate review: November 2026 prices, terms and what to verify
As of November 20, 2026, Calibrate is a brand-medication route rather than a compounded program: $199 a month with a 3-month commitment; "Lab tests and prescription medications are not included" (read on its own page). It is listed for comparison and is not part of this site’s computed ranking of compounded programs.
Released · Last reviewed · how we verify
Why no current price is shown
$199 a month with a 3-month commitment; "Lab tests and prescription medications are not included". This site publishes no figure rather than an estimate or an outdated price presented as current. The August 2026 capture is kept in the open dataset as history, dated.
How a brand route compares
Brand medication bought through a platform costs the manufacturer’s self-pay price plus the platform’s own fee. Zepbound vials start at $299 a month and Wegovy pens cost $349 a month (new patients $199 for two starting fills through December 31, 2026) when bought direct from LillyDirect or NovoCare. Brand Zepbound and Wegovy are FDA-approved; compounded versions are not. The brand price page lays out every dose, and the platform-fee analysis adds each platform’s fee to a full year.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does Calibrate charge a membership fee?
Yes. Calibrate charges a recurring fee of about $199 a month on top of medication, as its page showed on November 20, 2026, and this site folds that fee into every all-in figure.
Does Calibrate take insurance?
Not for compounded medication. Calibrate is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does Calibrate serve?
Calibrate’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Calibrate pricing page (read November 20, 2026)